Pfizer gets option to AnTolRx's lead project for Type I diabetes; option exercised
Executive Summary
Concurrent with leading AnTolRx Inc.'s $4mm Series A financing, Pfizer Inc. also received the exclusive option to in-license the start-up's Type I diabetes candidate should it hit certain undisclosed milestones.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Nanotechnology, Chips, etc.
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice